Soros Capital Management’s Denali Therapeutics DNLI Stock Holding History

Soros Capital Management’s Portfolio DNLI Stock Details DNLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-54,000	Closed	-$2.72M	–	47
2021 Q3	$2.72M	Hold	54,000	–	–	0.5%	27
2021 Q2	$4.24M	Buy	+54,000	New	+$3.34M	0.45%	39

Other funds holding DNLI

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Crestline Management Fort Worth, Texas $53.5M AUM 80.67% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return

Soros Capital Management's DNLI Position: Q4 2021 in Review

Soros Capital Management sold out of Denali Therapeutics (DNLI) in Q4 2021, closing a stake of 54,000 shares — an estimated $2.72M sold.

Soros Capital Management first reported a position in DNLI in Q2 2021 and held it in 2 quarters. The position peaked at $4.24M in Q2 2021. 213 funds tracked by Wall St. Rank hold DNLI as of Q4 2021.

Soros Capital Management reported no remaining Denali Therapeutics position as of Q4 2021 after selling out during the quarter.
Soros Capital Management sold 54,000 Denali Therapeutics shares in Q4 2021, an estimated $2.72M.
Soros Capital Management first reported a position in Denali Therapeutics in Q2 2021 and held it in 2 quarters.
Soros Capital Management's Denali Therapeutics position peaked at $4.24M in Q2 2021.
213 funds tracked by Wall St. Rank held Denali Therapeutics as of Q4 2021.

Based on Soros Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.